UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000014583
Receipt number R000016965
Scientific Title Analysis of efficacy and safety of antiviral therapy with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation
Date of disclosure of the study information 2014/08/20
Last modified on 2016/12/20 16:59:01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Analysis of efficacy and safety of antiviral therapy with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation

Acronym

Interferon-free therapy for posttransplant hepatitis C

Scientific Title

Analysis of efficacy and safety of antiviral therapy with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation

Scientific Title:Acronym

Interferon-free therapy for posttransplant hepatitis C

Region

Japan


Condition

Condition

hepatitis C after liver transplantation

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

To clarify the efficacy and safety of antiviral therapy with dacltasvir and asunaprevir for recurrent hepatitis C after liver transplantation

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Efficacy and safety of antiviral therapy with dacltasvir and asunaprevir for recurrent hepatitis C after liver transplantation

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Recurrent hepatitis C after liver transplantation
2. HCV genotype 1
3. 20 years old and over
4. Written informed consent for participation in this study is obtained

Key exclusion criteria

without abilty to understand informed consent

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshihide Ueda

Organization

Kyoto University Hospital

Division name

Gastroenterology and Hepatology

Zip code


Address

54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

TEL

075-751-4319

Email

yueda@kuhp.kyoto-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yoshihide Ueda

Organization

Kyoto University Hospital

Division name

Gastroenterology and Hepatology

Zip code


Address

54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

TEL

075-751-4319

Homepage URL


Email

yueda@kuhp.kyoto-u.ac.jp


Sponsor or person

Institute

Kyoto University Hospital

Institute

Department

Personal name



Funding Source

Organization

Health and Labor Sciences Research Grants for Research on Hepatitis from the Ministry of Health, Labor and Welfare, Japan

Organization

Division

Category of Funding Organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 08 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2014 Year 08 Month 20 Day

Date of IRB


Anticipated trial start date

2014 Year 08 Month 20 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

We will observe the efficacy and safety of anti-viral therapy with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation in Kyoto University, and analyze teh predictive factors of the efficacy and safety.


Management information

Registered date

2014 Year 07 Month 17 Day

Last modified on

2016 Year 12 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016965


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name